Johan Albrecht
Analyst · Pacific Crest. Your line is open
Thank you, Fried. I'll start with a brief review of our consolidated revenue on Slide 7. For clarity, I’d like to remind everyone that when we refer to sales in our presentation, we mean revenues plus net deferred revenues. Also please note that unless otherwise stated, all comparisons in this call are against our results for the first quarter of 2016. As Peter mentioned in his opening remarks in this year's quarter, we realized the 20% increase in revenue with double digit increases in all three of our segments. Materialise Software accounted for 27% of our total revenue. Materialise Medical for 31% and Materialise Manufacturing for 42%. As you know, two of our company's goals are to grow the contribution at software revenue and end parts revenue make to our total mix. This year's first quarter across all three of our segments, revenue from software sales and end parts contributed 75% of total revenue. The remaining 25% was generated through the production of prototypes. Moving to Slide 8, you will see our consolidated EBITDA numbers for the first quarter. As Peter mentioned earlier, consolidated adjusted EBITDA increased by 148%, increasing from €1,135,000 to €2,813,000. Our adjusted EBITDA margin doubled from 4.3% to 8.8%. These improvements primarily reflect three factors. First, of course our double digit revenue growth. Second, an improvement in manufacturing gross margin offset by higher cost of sales in medical. And third, an increase of only 7.4% in operational expenses. The high cost of sales in medical was due to increased activity in our medical devices and implants business lines which involved a higher cost of production. I should note that over time we expect our current gross margin to increase as we realize further scale effects and efficiency gains in both medical and manufacturing. Slide 9 summarizes the result of our Materialise Software segment for which revenue grew 15%. Revenue from recurring sales grew 22%. OEM sales grew 29% compared to last year's period. Segment EBITDA margin remain solid at approximately 35%. Turning to Slide 10, you will see that total revenue in our Materialise Medical segment grew 15% for the quarter. Revenue for Medical software sales increased 16%, driven by 27% growth in revenues generated from annual and renewal licenses. Just as in our software segment, the significant portion of the sales could not be recognized in the period and is part of the increased of deferred revenue. Software revenues represent a 36% of the total medical segment. Revenues from direct sales from medical collaboration, partners and direct sales from complex surgery each rose by 15% compared to the first quarter 2016. EBITDA for the medical segment was €314,000 as compared to a loss of €530,000 in the prior year period. EBITDA margin was up 940 basis points as a result of the higher revenues and only moderate growth of operational expenses more than offsetting the increase cost of sales. Now let's turn to Slide 11 for an overview of the first quarter performance of our Materialise Manufacturing segment. Their revenue rose 26%, fueled by revenue from end part manufacturing which was up 35% over last year's period. End parts accounted for 41% of the segment's revenue, up from 39% last year. EBITDA rose from €257,000 to €1,322,000. The margin increased 750 basis points to 9.9% this quarter from 2.4% last year, boosted by the revenue growth combined with improved cost of sales, efficiencies and only a moderate growth of operational expenses. The company's total number of printers grows to 155, up five of the number as of end 2016. Slide 12 provides the highlights of our income statements for the first quarter. Gross profit rose 16% compared to the last year's period, while gross margin was 57.9% as compared to 59.9%. Again, this primarily reflects increase activity in medical devices and implants which involved high cost of production. In total, R&D, sales and marketing and G&A spending rose by 7.4% over the prior year period. R&D and G&A each rose modestly while sales and marketing accounting for a larger proportion of the increased as we brought on more resources to enable us to support future revenue growth. We posted an operating loss of only €84,000 compared to €989,000 for quarter one 2016, an improvement of €905,000. The net financial result was negative €142,000 compared to a negative €734,000 for last year's period, reflecting smaller variances in the currency exchange rate primarily on the portion of the company's IPO proceeds out in US dollar. Net loss for the first quarter of 2017 was €816,000 compared to a loss of €3,151,000 for last year's period, the improvement in net loss includes beside the operational and financial variances already explained; a positive fluctuation of €1,059,000 in income taxes. Now please turn to Slide 13 for a recap of balance sheet and cash flow highlights. Our balance sheet remains strong with debt accounting for 24% of total liabilities and equity at the quarter end. Capital expenditures amounted to €9.6 million compared to €1.6 million in last year's period and include €4.4 million related to the premises under construction in Poland and Belgium. Cash flow from operations increased €1.6 million compared to €1.4 million last year. We ended the quarter with cash and cash equivalents of €55.1 million compared to €55.9 million as of December 31, 2016. Total deferred income amounted to €23.5 million compared to €21.4 million as of year end and €18.2 million as of March 31, 2016. With that overview, I'll turn the call back to Peter.